248 related articles for article (PubMed ID: 37864163)
1. Elesclomol, a copper-transporting therapeutic agent targeting mitochondria: from discovery to its novel applications.
Tarin M; Babaie M; Eshghi H; Matin MM; Saljooghi AS
J Transl Med; 2023 Oct; 21(1):745. PubMed ID: 37864163
[TBL] [Abstract][Full Text] [Related]
2. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells.
Nagai M; Vo NH; Shin Ogawa L; Chimmanamada D; Inoue T; Chu J; Beaudette-Zlatanova BC; Lu R; Blackman RK; Barsoum J; Koya K; Wada Y
Free Radic Biol Med; 2012 May; 52(10):2142-50. PubMed ID: 22542443
[TBL] [Abstract][Full Text] [Related]
3. Novel insights into anticancer mechanisms of elesclomol: More than a prooxidant drug.
Gao J; Wu X; Huang S; Zhao Z; He W; Song M
Redox Biol; 2023 Nov; 67():102891. PubMed ID: 37734229
[TBL] [Abstract][Full Text] [Related]
4. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.
Zheng P; Zhou C; Lu L; Liu B; Ding Y
J Exp Clin Cancer Res; 2022 Sep; 41(1):271. PubMed ID: 36089608
[TBL] [Abstract][Full Text] [Related]
5. The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II).
Hasinoff BB; Yadav AA; Patel D; Wu X
J Inorg Biochem; 2014 Aug; 137():22-30. PubMed ID: 24798374
[TBL] [Abstract][Full Text] [Related]
6. Elesclomol induces copper-dependent ferroptosis in colorectal cancer cells via degradation of ATP7A.
Gao W; Huang Z; Duan J; Nice EC; Lin J; Huang C
Mol Oncol; 2021 Dec; 15(12):3527-3544. PubMed ID: 34390123
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial electron transport is the cellular target of the oncology drug elesclomol.
Blackman RK; Cheung-Ong K; Gebbia M; Proia DA; He S; Kepros J; Jonneaux A; Marchetti P; Kluza J; Rao PE; Wada Y; Giaever G; Nislow C
PLoS One; 2012; 7(1):e29798. PubMed ID: 22253786
[TBL] [Abstract][Full Text] [Related]
8. 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer.
Yang W; Wang Y; Huang Y; Yu J; Wang T; Li C; Yang L; Zhang P; Shi L; Yin Y; Tao K; Li R
Biomed Pharmacother; 2023 Mar; 159():114301. PubMed ID: 36706634
[TBL] [Abstract][Full Text] [Related]
9. Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II).
Hasinoff BB; Wu X; Yadav AA; Patel D; Zhang H; Wang DS; Chen ZS; Yalowich JC
Biochem Pharmacol; 2015 Feb; 93(3):266-76. PubMed ID: 25550273
[TBL] [Abstract][Full Text] [Related]
10. The evaluation of the anti-cancer drug elesclomol that forms a redox-active copper chelate as a potential anti-tubercular drug.
Ngwane AH; Petersen RD; Baker B; Wiid I; Wong HN; Haynes RK
IUBMB Life; 2019 May; 71(5):532-538. PubMed ID: 30698324
[TBL] [Abstract][Full Text] [Related]
11. The Anticancer Agent Elesclomol Has Direct Effects on Mitochondrial Bioenergetic Function in Isolated Mammalian Mitochondria.
Modica-Napolitano JS; Bharath LP; Hanlon AJ; Hurley LD
Biomolecules; 2019 Jul; 9(8):. PubMed ID: 31344923
[TBL] [Abstract][Full Text] [Related]
12. Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma.
Li Y; Yang J; Zhang Q; Xu S; Sun W; Ge S; Xu X; Jager MJ; Jia R; Zhang J; Fan X
Oncogene; 2022 Jul; 41(27):3539-3553. PubMed ID: 35697803
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II).
Yadav AA; Patel D; Wu X; Hasinoff BB
J Inorg Biochem; 2013 Sep; 126():1-6. PubMed ID: 23707906
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of resveratrol is independent of Cu(II) complex formation in MCF-7 cell line.
Andrade Volkart P; Benedetti Gassen R; Mühlen Nogueira B; Nery Porto B; Eduardo Vargas J; Arigony Souto A
Bioorg Med Chem Lett; 2017 Aug; 27(15):3238-3242. PubMed ID: 28647350
[TBL] [Abstract][Full Text] [Related]
15. Targeting cuproplasia and cuproptosis in cancer.
Tang D; Kroemer G; Kang R
Nat Rev Clin Oncol; 2024 May; 21(5):370-388. PubMed ID: 38486054
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations.
Cierlitza M; Chauvistré H; Bogeski I; Zhang X; Hauschild A; Herlyn M; Schadendorf D; Vogt T; Roesch A
Exp Dermatol; 2015 Feb; 24(2):155-7. PubMed ID: 25453510
[TBL] [Abstract][Full Text] [Related]
17. Elesclomol restores mitochondrial function in genetic models of copper deficiency.
Soma S; Latimer AJ; Chun H; Vicary AC; Timbalia SA; Boulet A; Rahn JJ; Chan SSL; Leary SC; Kim BE; Gitlin JD; Gohil VM
Proc Natl Acad Sci U S A; 2018 Aug; 115(32):8161-8166. PubMed ID: 30038027
[TBL] [Abstract][Full Text] [Related]
18. Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT/mTOR pathway in prostate cancer.
Wen H; Qu C; Wang Z; Gao H; Liu W; Wang H; Sun H; Gu J; Yang Z; Wang X
FASEB J; 2023 Sep; 37(9):e23145. PubMed ID: 37584654
[TBL] [Abstract][Full Text] [Related]
19. Elesclomol induces cancer cell apoptosis through oxidative stress.
Kirshner JR; He S; Balasubramanyam V; Kepros J; Yang CY; Zhang M; Du Z; Barsoum J; Bertin J
Mol Cancer Ther; 2008 Aug; 7(8):2319-27. PubMed ID: 18723479
[TBL] [Abstract][Full Text] [Related]
20. Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD-L1 for Enhanced Cancer Immunotherapy.
Guo B; Yang F; Zhang L; Zhao Q; Wang W; Yin L; Chen D; Wang M; Han S; Xiao H; Xing N
Adv Mater; 2023 Jun; 35(22):e2212267. PubMed ID: 36916030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
